Patents by Inventor Nicholas M. Gough

Nicholas M. Gough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5629283
    Abstract: The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibodies thereto.
    Type: Grant
    Filed: November 23, 1994
    Date of Patent: May 13, 1997
    Assignee: Amrad Corporation Limited
    Inventors: Nicos A. Nicola, Nicholas M. Gough, David P. Gearing, Donald Metcalf, Julie A. King
  • Patent number: 5602007
    Abstract: This invention provides a DNA sequence coding for a mammalian granulocyte macrophage colony stimulating factor (GM-CSF), a method of obtaining same, vectors and hosts harboring same. The sequence is useful as a probe for identifying related sequences, selecting GM-CSF encoding mRNA from a mixture of mRNAs containing same, and a source of GM-CSF DNA for expression in an appropriate expression vector. The GM-CSF protein encoded by the sequence is useful for stimulating the production of granulocytes and macrophages from their respective progenitor cells.
    Type: Grant
    Filed: December 9, 1988
    Date of Patent: February 11, 1997
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Ashley R. Dunn, Nicholas M. Gough, Donald Metcalf
  • Patent number: 5443825
    Abstract: Leukemia-inhibitory factor (LIF) has been produced in essentially pure form from murine or human sources. A method of purifying this LIF is disclosed, as well as polypeptides having LIF activity which are not identical in amino acid sequence to any naturally occurring form of LIF. The polypeptides can be used for hindering the proliferation of myeloid Leukemia cells.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: August 22, 1995
    Assignee: Amrad Corporation Limited
    Inventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
  • Patent number: 5427925
    Abstract: The present invention provides a method for producing recombinant leukemia inhibitory factor (LIF) by the expression, in suitable host cells, of recombinant DNA molecules encoding LIF.
    Type: Grant
    Filed: May 6, 1993
    Date of Patent: June 27, 1995
    Assignee: Amrad Corporation Limited
    Inventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
  • Patent number: 5418159
    Abstract: The present invention relates generally to the isolation of leukaemia inhibitory factor (LIF) genes from livestock species, the expression of said genes in recombinant vectors and the isolation of the recombinant LIF molecules and the use of livestock species LIF to enhance the in vitro development of an embryo to the implantation stage.
    Type: Grant
    Filed: August 29, 1991
    Date of Patent: May 23, 1995
    Assignee: Amrad Corporation Limited
    Inventors: Nicholas M. Gough, Tracey A. Willson, Robert F. Seamark
  • Patent number: 5187077
    Abstract: A leukaemia-inhibitory factor (LIF) is disclosed, together with a method of preparation of LIF in essentially pure form. Nucleotide and amino acid sequences are disclosed, together with recombinant DNA moleclues and host cells for production of polypeptides having LIF activity.
    Type: Grant
    Filed: December 9, 1988
    Date of Patent: February 16, 1993
    Assignee: Amrad Corporation Limited
    Inventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
  • Patent number: 5166065
    Abstract: The present invention relates generally to the use of leukaemia inhibitory factor (LIF) in the maintenance and derivation of embryonic stem (ES) cells in culture. The ES cells are maintained and/or derived from animal embryos by culturing said cells or embryos in a culture medium containing an effective amount of LIF for a time and under conditions sufficient to maintain and/or derive said ES cells. The ES cells may be passaged in LIF and used to make chimaeric animals.
    Type: Grant
    Filed: May 31, 1990
    Date of Patent: November 24, 1992
    Assignee: Amrad Corporation Limited
    Inventors: Robert L. Williams, Nicholas M. Gough, Douglas J. Hilton